Search Results
Your search for where matches 5550 pages
Showing 4501 - 4550Paging Dr. Google: Practicing Oncology in the Era of Social Media and Telemedicine
Over the past few decades, economic and political factors have reshaped oncology, especially in the community setting. To defray risk, we’ve seen a trend toward oncology practices partnering with hospitals or aggregating into larger networks. Moreover, the Internet and the advent of telemedicine...
Platinum Agents in Triple-Negative Breast Cancer: Encouraging New Data
For the treatment of triple-negative breast cancer, there is renewed interest in investigating the role of platinum chemotherapy, according to Melinda L. Telli, MD, Assistant Professor of Medicine at Stanford University, Palo Alto. At the Best of ASCO meeting in Los Angeles, Dr. Telli reviewed the...
What You Need to Know About E-Cigarettes
“I’ve seen a lot of puzzled people,” Alexander V. Prokhorov, MD, PhD, said, referring to people who see others using electronic or e-cigarettes. That puzzlement can go beyond wondering why people are smoking in public places and whether they are breaking the law, or just being annoying, to...
Straight Talk: The Future of Medical and Health Research
Nearly 200 scientists and stakeholders in the research community attended Research!America’s National Health Research Forum on September 12, at the Newseum’s Knight Conference Center in Washington, DC. Research!America’s President and CEO, Mary Woolley, opened the program. “The theme for this...
William E. Evans, MD, Director, St. Jude Children's Research Hospital, to Retire in July 2014
St. Jude Children’s Research Hospital recently announced that William E. Evans, MD, Director and CEO, has decided to retire from his executive post in July of 2014. Dr. Evans has been with the organization for more than 40 years and has served as CEO for the past 10 years. Indelible Mark on History ...
Donatori di Musica Initiative Creates a Unique Environment for Oncology Patients
“Surely again, to heal men’s wounds by music’s spell.” —Euripides, Medea (480-406 BC) Commonly defined as organized sound, music has a unique power to stir human emotions, moods, and impressions. The salutary effect of music on the sick has been reported since antiquity. Aristotle and Plato wrote...
Felice Schnoll-Sussman, MD, Named Director of Jay Monahan Center for Gastrointestinal Health at NewYork-Presbyterian/Weill Cornell
NewYork-Presbyterian/Weill Cornell Medical Center has appointed Felice Schnoll-Sussman, MD, Director of its Jay Monahan Center for Gastrointestinal Health. Dr. Schnoll-Sussman, has served as the Center’s Director of Research since 2007 and Acting Director since 2012. As Director, Dr....
Advances in Medical Oncology Over the Next Decade
The next 10 years are expected to usher in unprecedented advances in oncology, including molecularly driven diagnostic and therapeutic developments, whole genome sequencing that results in true precision-based medicine, survivorship care plans that address long-term quality of life concerns, and...
ASTRO Offers Five Recommendations as Part of Choosing Wisely Campaign
The American Society for Radiation Oncology (ASTRO) released its list of five radiation oncology-specific treatments that are commonly ordered but may not always be appropriate as part of the national Choosing Wisely® campaign, an initiative of the American Board of Internal Medicine Foundation....
View From a Cancer Ward in Botswana
Julie Livingston, PhD, MPH, is a Professor of History at Rutgers University. She is also an African historian with interdisciplinary training in public health and anthropology. Among other issues, her work considers the challenges of delivering oncology services in southern Africa, where there is a ...
A Great IDEA: Supporting the Next Generation of Oncology Leaders in Low- and Middle-Income Countries
Leadership has been cited as a critical success factor for improving access to cancer care in low- and middle-income countries.1 Effective clinical leaders in these countries can be transformative by supporting the development of cancer treatments to meet the needs of their patients, by advocating...
Comparative Effectiveness Research: Its Time Has Arrived
Reigning in the nation’s runaway medical costs was an underlying theme of President Obama’s health-care reform platform. Citing projects like The Dartmouth Atlas of Health Care, which documented large gaps in the quality, costs, and outcomes of health services around the country, the...
Germline Mutations and Breast Cancer Prognosis: Does the Cause Matter?
Since the discovery of BRCA1 and BRCA2, investigators have sought to determine whether the presence of a germline mutation independently influences the outcome of a breast cancer diagnosed in a woman with an inherited mutation. The question is highly relevant to an unaffected woman with a mutation, ...
New President and CEO of Fox Chase Cancer Center Reflects on Challenges and Opportunities Ahead
On October 8, 1904, a group of Philadelphia physicians and businessmen who were concerned about the escalating incidence of cancer in the city signed a charter that established the American Oncologic Hospital, one of the nation’s first hospitals solely devoted to cancer care. Seven decades later—2...
Stereotactic Body Radiation Therapy Offers Near-Complete Tumor Control for Medically Inoperable Early-Stage NSCLC
Patients with stage I non–small cell lung cancer (NSCLC) who are medically inoperable have an excellent chance at full local tumor control and long-term survival with stereotactic body radiation therapy. Hak Choy, MD, Professor and Chairman of the Department of Radiation Oncology at The University...
Ancient Chinese Military Tactics Might Help Win the War on Lung Cancer
At the 14th International Lung Cancer Congress, held recently in Huntington Beach, California, Tony S.K. Mok, MD, Professor of Clinical Oncology at the Chinese University of Hong Kong, was the honored recipient of the Bonnie J. Addario Lung Cancer Foundation Award. The award was presented by Ms....
Important Findings in Metastatic Colorectal Cancer Studies Address Treatment, Management Options
At the Best of ASCO Meeting in Los Angeles, Tony Reid, MD, PhD, Director of the Early Phase Clinical Research Program and Professor of Hematology/Oncology at the University of California, San Diego, reviewed important findings in metastatic colorectal cancer presented at the 2013 ASCO Annual...
FDA Grants Breakthrough Therapy Status to Entinostat for Advanced Breast Cancer
Syndax Pharmaceuticals Inc announced that the U.S. Food and Drug Administration (FDA) has designated entinostat as a Breakthrough Therapy for the treatment of locally recurrent or metastatic estrogen receptor (ER)-positive breast cancer when added to exemestane in postmenopausal women whose disease ...
Applying Molecular Profiling to Clinical Practice: Promises and Challenges
A “new kind of pathology,” with anatomy and histology being supplemented by molecular etiology, has been emerging over the past decade and promises better response rates among patients with cancer, as genomic alterations continue to be identified and treated with targeted therapies. “The list of...
Pathologic Complete Response as a Test Bed for Novel Therapies: Proceed—With Caution!
Pathologic complete response as assessed surgically after neoadjuvant treatment is being touted by some researchers as a stand-alone endpoint justifying early drug approval for breast cancer. They argue that it provides a more efficient means of testing the value of agents that might be useful in...
Expert Point of View: Steven J. O’Day, MD
Steven J. O’Day, MD, Director of Clinical Research at the Beverly Hills Cancer Center and Adjunct Member of the John Wayne Cancer Institute in Los Angeles, said, “This is an important study. It allows us to feel comfortable with our aggressive approach to the management of DCIS.” Dr. O’Day...
Single-Institution Study Evaluates Routine Use of Perioperative MRI in Patients With Ductal Carcinoma In Situ
Perioperative MRI for patients with ductal carcinoma in situ (DCIS) was not associated with a reduction in locoregional recurrence or contralateral breast cancer development in a large single-center study reported at the 2013 ASCO Breast Cancer Symposium. The study also was presented at a...
Trying to Improve Value in Cancer Care: An Experiment
One of the more significant problems in modern oncology practice is to provide increased value at a time when costs are spiraling upward, and new parameters of “success” are being introduced into the equation—most visibly, inside the Beltway in Washington, DC. Thus, oncologists will need to address ...
Breast Cancer Care in the Era of Accountable Care Organizations
Prepare for big changes ahead, Lawrence N. Shulman, MD, Senior Vice President for Medical Affairs at the Dana-Farber Cancer Institute, Brigham and Women’s Hospital, and Harvard Medical School in Boston, told oncologists at the 2013 Breast Cancer Symposium.1 One change is the emergence of...
Front-Line Treatment Strategies to Achieve Long-Term Control of CLL Combined With Optimal Quality of Life
“The management of chronic lymphocytic leukemia (CLL) is undergoing profound changes. Several new drugs have been approved for CLL treatment (fludarabine, bendamustine [Treanda], and the monoclonal antibodies alemtuzumab [Campath], rituximab [Rituxan], and ofatumumab [Arzerra]), and many more drugs ...
Better Risk Communication Strategies Needed to Ensure Decision to Have Contralateral Prophylactic Mastectomy Is Evidence-Based
Overestimating the risk that cancer in one breast will affect the other breast may cause many young women with breast cancer to choose contralateral prophylactic mastectomy even though most know it does not clearly improve survival. In a survey of 123 women who were diagnosed with cancer in one...
Claudia I. Henschke, PhD, MD, Took a Circuitous Route to Her Groundbreaking Work in Lung Cancer Screening
“Once you have tasted flight, you will forever walk the earth with your eyes turned skyward, for there you have been, and there you will always long to return.” —Leonardo da Vinci Lung cancer CT screening may have had no greater advocate than Claudia I. Henschke, PhD, MD. In the face of...
Innovation Impact Awards Support Efforts to Advance Blood Cancer Research Priorities and Lung Cancer Screening Adoption
Celgene Corporation recently announced the two recipients of Celgene’s inaugural Innovation Impact Awards: The Aplastic Anemia & Myelodysplastic Syndromes International Foundation (AA&MDSIF) and the Lung Cancer Alliance. The Innovation Impact Awards program recognizes effective, innovative, ...
'Master Protocol' Could Revolutionalize Trials in Lung Cancer, and Eventually Other Cancers
Cancer advocates and clinical trialists, for some time, have been proposing a radical change to the laborious drug development process—that industry, academia, funding sources, and other stakeholders actually pool their brain power and financial means and work together, not separately, to develop...
A Look Ahead: How the FDA Is Adapting in the Era of Precision Medicine
Dubbed “Cancer Czar” by the media, Richard Pazdur, MD, Director of the U.S. Food and Drug Administration (FDA) Office of Hematology and Oncology Products, said he has the “best job in oncology, with a unique vantage point in cancer drug development.” An oncologist for more than 30 years—including...
ASCO President-Elect Candidate Julie M. Vose, MD, MBA, FASCO
Cost of Care and Federal Funding How can ASCO address the high cost of cancer care and diminishing federal resources for basic and translational research? We need to work with the Centers for Medicare & Medicaid Services, private insurers, and health-care systems to encourage evidence-based...
ASCO President-Elect Candidate Lynn M. Schuchter, MD, FASCO
Cost of Care and Federal Funding How can ASCO address the high cost of cancer care and diminishing federal resources for basic and translational research? In answer to the first part of this question, the rising cost of cancer care has certainly become a focus of national conversation given the...
Penn Medicine Names D. Gary Gilliland, MD, PhD, First Leader of Precision Medicine
Dr. Gary Gilliland, MD, PhD, has been named the inaugural Vice Dean and Vice President for Precision Medicine, at Penn Medicine, University of Pennsylvania in Philadelphia. Dr. Gilliland is a cancer genetics expert and pioneer in the development of targeted therapies. “We are proud to be among the...
Take-Home Messages From the NCCN Hematologic Malignancies Conference
As the National Comprehensive Cancer Network (NCCN) 8th Annual Congress: Hematologic Malignancies was drawing to a close, The ASCO Post spoke with Andrew D. Zelenetz, MD, PhD, about the themes of the meeting and the take-home messages for attendees and for our readers. Dr. Zelenetz is Vice Chair...
Expert Point of View: Josep Tabernero, MD, PhD and Eric Van Cutsem, MD, PhD
At the European Cancer Congress (ECC), Josep Tabernero, MD, PhD, Head of the Medical Oncology Department at Vall d’Hebron University in Barcelona, Spain, noted that the ASPECCT study asks a “reasonable question about the efficacy and safety of the two clinically approved anti-EGFR antibodies” and...
Aspirin Protects Against Colorectal Cancer Recurrence in PIK3CA-Mutant Tumors
At the 2013 European Cancer Congress, two investigative teams attempted to explain how aspirin may protect against colorectal cancer recurrences, with one study showing PIK3CA mutations associated with protection from aspirin, but not a COX-2 inhibitor, and the other study implicating HLA class I...
Optimizing Anti-HER2 Treatment for Metastatic Breast Cancer in 2013
The good news about HER2-positive breast cancer is that recurrent disease is plummeting, owing to the impact of adjuvant trastuzumab [Herceptin]. Hopefully, first-line metastatic treatment is becoming a thing of the past,” said Harold Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston....
Novel Anti–PD-L1 Antibody Produces Durable Responses in Metastatic NSCLC, Smokers Included
The engineered monoclonal antibody MPDL3280A achieved encouraging and durable responses in a phase I study in metastatic non–small cell lung cancer (NSCLC) in both smokers and nonsmokers, as well as in cancers of squamous and adenocarcinoma histology. Responses were more robust in smokers than...
'Clear and Consistent Protective Effect of Marriage' Found in Patients With 10 Most Clinically Significant Cancers
A clear and consistent protective effect of marriage among patients harboring one of the 10 most clinically significant malignancies affecting Americans” was found in a study analyzing Surveillance, Epidemiology, and End Results (SEE) data for 734,889 patients diagnosed with lung, colorectal,...
Advancing Psychosocial Oncology Care Over the Next Decade
A psychiatrist for more than 40 years, Jimmie C. Holland, MD, Attending Psychiatrist and Wayne E. Chapman Chair at Memorial Sloan-Kettering Cancer Center and Professor of Psychiatry, Weill Medical College of Cornell University in New York, is internationally recognized as the founder of the...
Multicenter Analysis of Outcomes of Lymphoma in Pregnancy
Lymphoma is the fourth most frequent cancer to occur in pregnant women. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, Chief of Hematology/Oncology at Tufts University Medical Center, Boston, and colleagues examined treatment,...
New Report Examines Trends in End-of-Life Care
Although fewer Medicare patients with cancer died in the hospital in 2010 than in the years 2003–2007, aggressive treatment continues at the end of life, according to a new report from the Dartmouth Atlas Project.1 The findings also show that a significant number of patients were likely to receive...
ASCO Announces Inaugural Class for Quality Training Program
For oncologists, continuous quality improvement is a key goal. We measure and assess the quality of care we deliver and constantly look for areas where we can do better,” said ASCO President Clifford A. Hudis, MD, FACP. “ASCO’s Quality Training Program will guide oncology care providers in...
Celebrating 30 Years of Mentorship That Makes a Difference
The Conquer Cancer Foundation (CCF) Grants and Awards Program has been instrumental in helping launch the careers of hundreds of aspiring cancer researchers around the world over the past 30 years. Since the first grant provided in 1984, Conquer Cancer Foundation–funded scientists have become some...
ASCO Reconfirms Commitment to Choosing Wisely® Campaign
In collaboration with the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign, ASCO recently released a second “Top Five” opportunities list of common practices or procedures in oncology whose clinical value is not supported by available evidence and if eliminated, can ...
Technologic Innovations Are Likely to Transform Oncology Care
Oncology and medicine as a whole are likely to benefit from a variety of technologic innovations recently showcased at the third annual The Atlantic Meets the Pacific symposium, according to Peter P. Yu, MD, President-Elect of the American Society of Clinical Oncology, and medical oncologist and...
Neoadjuvant Treatment of Early Breast Cancer
INSIDE THE BLACK BOX is an occasional column providing insight into the FDA and its policies and procedures. In this first installment, FDA Clinical Reviewers Laleh Amiri-Kordestani, MD, and Suparna Wedam, MD, discuss FDA’s recent approval of pertuzumab (Perjeta) for the neoadjuvant treatment of...
Oncogene Addiction and the Rationale for Molecular Targeted Therapy in Lung Cancer
Over the past decade, Fadlo R. Khuri, MD, Professor and Roberto C. Goizueta Distinguished Chair of Hematology and Medical Oncology, and Deputy Director of the Winship Cancer Institute of Emory University, Atlanta, has focused his research and clinical career on investigating novel approaches in the ...
One Dose of HPV 16/18 Vaccine Produces Durable Response, Study Finds
Results from the Costa Rica HPV 16/18 Vaccine Trial indicate that 4-year efficacy against 12-month HPV 16/18 persistent infection was similarly high among women who received one, two, or the recommended three doses of the bivalent HPV16/18 L1 virus-like particle vaccine (Cervarix). The findings...
Expert Point of View: Rebecca Kristeleit, MD
Formal discussant of the AURELIA and ICON7 presentations, Rebecca Kristeleit, MD, University College London Hospital, London, said that a consistent message in both trials was the benefit of bevacizumab (Avastin) in high-risk disease. “Angiogenesis seems to be a particular driver of advanced...
